NCT01381679

Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)

Austrian Cholesterol Screening And Treatment II (ACT II)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,682 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol Screening and Treatment project (ACT I), which assessed the cholesterol status, including achievement of the target levels applicable at that time (LDL levels \<100 mg/dL), in participants with coronary heart disease (CHD) already being treated with a statin. In this study, participants without adequate LDL-cholesterol reduction with a statin underwent extension of therapy with ezetimibe with the goal of achieving target levels.

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	Ezetimibe	Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.

Timeline

• Start date: 2009-05-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2011-06-27
• Last updated: 2022-02-09
• Results posted: 2012-03-22